Stock DMYD B DIAMYD MEDICAL AB
Add to a list
To use this feature you must be a member
Log inSign up

Diamyd Medical AB Stock

Equities

DMYD B

SE0005162880

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm
Other stock markets
 11:29:58 2024-05-31 am EDT 		5-day change 1st Jan Change
11.58 SEK -2.36% Intraday chart for Diamyd Medical AB +0.87% +76.26%
May. 16 Diamyd Medical AB Updates on the Registrational Phase 3 Trial CI
Apr. 18 Diamyd Medical Raises SEK57 Million in Rights Issue MT

Financials

Sales 2024 * 3M 285K Sales 2025 * 3M 285K Capitalization 1.15B 110M
Net income 2024 * -133M -12.64M Net income 2025 * -165M -15.68M EV / Sales 2024 * 339 x
Net cash position 2024 * 139M 13.21M Net cash position 2025 * 30M 2.85M EV / Sales 2025 * 375 x
P/E ratio 2024 *
-8.71 x
P/E ratio 2025 *
-7.02 x
Employees 26
Yield 2024 *
-
Yield 2025 *
-
Free-Float 63.2%
More Fundamentals * Assessed data

Chart Diamyd Medical AB

Dynamic Chart

Latest news about Diamyd Medical AB

Diamyd Medical AB Updates on the Registrational Phase 3 Trial CI
Diamyd Medical Raises SEK57 Million in Rights Issue MT
Recruitment Milestone Reaches in Diamyd® Phase 3 Trial CI
Diamyd Medical AB Reports Earnings Results for the Second Quarter and Six Months Ended February 29, 2024 CI
Diamyd Medical to Raise SEK114 Million Via Share Offering MT
Diamyd Medical to Present New Genetic Data at the ASIT Summit in Boston, MA CI
Diamyd Medical Secures US FDA Fast Track Designation for Type 1 Diabetes Treatment MT
In-Depth Analysis of Diamyd Medical AB's Phase II Trial Further Supports Value of Presented Insulin Production CI
Diamyd Medical AB Reports Earnings Results for the First Quarter Ended November 30, 2023 CI
Diamyd Medical S.A. Announces Interim Analysis of the Transformational Gene-Based Precision Medicine Phase 3 Trial, DIAGNODE-3, for Type 1 Diabetes Is Planned for July 2024 CI
Certain B Shares of Diamyd Medical AB are subject to a Lock-Up Agreement Ending on 27-DEC-2023. CI
Diamyd Medical's Precision Medicine Patent for the Prevention and Treatment of Autoimmune Diabetes Granted in South Korea CI
Diamyd Medical AB Elects Karin Rosén as A New Member of the Board CI
Diamyd Medical Partners With DiaUnion for Diabetes Drug Trial MT
Diamyd Medical Partners with Diamyd Medical to Recruit Participants for Type 1 Diabetes Prevention Trial CI
More news

Latest transcript on Diamyd Medical AB

Logo Diamyd Medical AB
Diamyd Medical AB - Special Call
More transcripts

Press releases Diamyd Medical AB

Diamyd Medical updates on the registrational Phase 3 trial; upcoming interim analysis and enrollment AQ
Diamyd Medical announces final outcome in the company's rights issue AQ
Diamyd Medical announces preliminary outcome in the company's rights issue AQ
Recruitment milestone reached in Diamyd® Phase 3 trial AQ
Diamyd Medical led ASSET innovation partnership organizes a workshop on the future treatment of Type 1 Diabetes AQ
More press releases

Quotes and Performance

1 day-2.36%
1 week+0.87%
1 month+8.43%
3 months-21.44%
6 months+64.26%
Current year+76.26%
More quotes

Highs and lows

1 week
11.12
Extreme 11.12
12.26
1 month
10.32
Extreme 10.32
13.30
Current year
6.47
Extreme 6.47
20.00
1 year
6.41
Extreme 6.41
20.00
3 years
6.41
Extreme 6.41
39.84
5 years
6.29
Extreme 6.29
74.70
10 years
2.85
Extreme 2.85
74.70
More quotes

Managers and Directors - Diamyd Medical AB

Managers TitleAgeSince
Ulf Hannelius CEO
 Chief Executive Officer 49 16-04-09
Anders Essen-Möller FOU
 Founder 83 95-12-31
Anna Styrud DFI
 Director of Finance/CFO 63 09-12-31
Members of the board TitleAgeSince
Anders Essen-Möller FOU
 Founder 83 95-12-31
Erik Kjellsson Nerpin BRD
 Director/Board Member 63 11-12-31
Karin Hehenberger BRD
 Director/Board Member 52 21-04-27
More insiders

Quotes

Date Price Change Volume
24-05-31 11.58 -2.36% 147,946
24-05-30 11.86 +4.96% 163,458
24-05-29 11.3 -2.42% 207,412
24-05-28 11.58 -0.34% 318,190
24-05-27 11.62 +1.22% 128,679

Delayed Quote Nasdaq Stockholm, May 31, 2024 at 11:29 am EDT

More quotes

Company Profile

Diamyd Medical AB is a Sweden-based diabetes company. It is active in the field of pharmaceutical development and investments in stem cell and medical technology. The Company develops the diabetes vaccine, Diamyd, with the active glutamic acid decarboxylase (GAD) ingredient for the treatment and prevention of autoimmune diabetes. The vaccine is intended for the treatment of children and adolescents with recent-onset type one diabetes, as well as those at high risk of developing the disease.
Sector
Biotechnology & Medical Research
Calendar
2024-06-25 - Q3 2024 Earnings Release
More about the company

Income Statement Evolution

More financial data

Ratings for Diamyd Medical AB

Trading Rating
Investor Rating
ESG Refinitiv
D
More Ratings

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
DIAMYD MEDICAL AB Stock Diamyd Medical AB
+76.26% 110M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+11.91% 118B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+11.60% 106B
BIONTECH SE Stock BioNTech SE
-4.68% 24.28B
ARGENX SE Stock argenx SE
-0.82% 21.96B
GENMAB A/S Stock Genmab A/S
-10.12% 18.16B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-42.12% 16.37B
BEIGENE, LTD. Stock BeiGene, Ltd.
-17.47% 15.56B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+2.77% 13.63B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+34.58% 12.27B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. DMYD B Stock